TO THE EDITOR:

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy approved for the treatment of patients with relapsed or chemo-refractory large B-cell lymphomas (LBCL). Axi-cel induced durable remissions with a ZUMA-1 (Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma) overall response rate (ORR) and complete response rate (CR) of 83% and 58%, respectively, with 39% progression-free survival (PFS) 2 years postinfusion.1,2  However, the majority of axi-cel–treated patients will ultimately experience disease progression. Only limited data exist on patients with progressive disease (PD) after anti-CD19 CAR-T therapy for LBCL.3,4  Because axi-cel currently accounts for the majority of CAR-T infusions in the United States, data regarding therapeutic options after progression are of great interest.5,6 

The US Lymphoma CAR-T Cell Consortium is a group of 17 US centers certified for treatment...

REFERENCES

REFERENCES
1.
Locke
FL
,
Ghobadi
A
,
Jacobson
CA
, et al
.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
.
Lancet Oncol
.
2019
;
20
(
1
):
31
-
42
.
2.
Neelapu
SS
,
Locke
FL
,
Bartlett
NL
, et al
.
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
.
N Engl J Med
.
2017
;
377
(
26
):
2531
-
2544
.
3.
Chow
VA
,
Gopal
AK
,
Maloney
DG
, et al
.
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy
.
Am J Hematol
.
2019
;
94
(
8
):
E209
-
E213
.
4.
Byrne
M
,
Oluwole
OO
,
Savani
B
,
Majhail
NS
,
Hill
BT
,
Locke
FL
.
Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy
.
Biol Blood Marrow Transplant
.
2019
;
25
(
11
):
e344
-
e351
.
5.
Pasquini
MC
,
Locke
FL
,
Herrera
AF
, et al
.
Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US) [abstract]
.
Blood
.
2019
;
134
(
suppl 1
). Abstract
764
.
6.
Jaglowski
S
,
Zhen-Huan
H
,
Zhang
Y
, et al
.
Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry [abstract]
.
Blood
.
2019
;
134
(
suppl 1
). Abstract
766
.
7.
Nastoupil
LJ
,
Jain
MD
,
Feng
L
, et al
.
Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium
.
J Clin Oncol
.
2020
;
38
(
27
):
3119
-
3128
.
8.
Neelapu
SS
,
Rossi
JM
,
Jacobson
CA
, et al
.
CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel [abstract]
.
Blood
.
2019
;
134
(
suppl 1
). Abstract
203
.
9.
Oak
J
,
Spiegel
JY
,
Sahaf
B
, et al
.
Target antigen downregulation and other mechanisms of failure after axicabtagene ciloleucel (CAR19) therapy [abstract]
.
Blood
.
2018
;
132
(
suppl 1
). Abstract
4656
.
10.
Logue
JM
,
Zucchetti
E
,
Bachmeier
CA
, et al
.
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma [published online ahead of print 23 April 2020]
.
Haematologica
.
doi: 10.3324/haematol.2019.238634
.
You do not currently have access to this content.

Sign in via your Institution

Sign In